Physician profile
Brandy A Hammond
NPI 1659443745
$6,427.69
in general payments reported to CMS, 2019-2025
12 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $596 · 2022: $1,621 · 2023: $1,269 · 2024: $954 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,014 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,014.02 |
| Education | $196.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,408.52 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,359.53 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,133.65 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $616.72 | 2021-2025 | Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $572.41 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $454.58 | 2024-2025 | Cobenfy |
| Abbvie INC. | $271.25 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $259.86 | 2022-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $236.72 | 2022-2024 | Ingrezza |
| Indivior INC. | $60.58 | 2023-2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $35.34 | 2022 | |
| Noven Therapeutics, LLC | $18.53 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.